Ovarian cancer, Solid tumor/s, Cancer, Breast cancer, Endometrial cancer
IMCRImmunocore HoldingsCatalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for IMC-F106C (Brenetafusp) in Ovarian cancer, Solid tumor/s, Cancer, Breast cancer, Endometrial cancer. The expected timing is based on the latest available company guidance and may change.
9/9/22- Initial Ph1 data presented. 5/8/24- Report data NSCLC in Q4 2024. 9/14/24- Presents Ph1 data from ovarian cancer at ESMO '24. 2/26/25- Trial ongoing. 11/06/25:- Phase 1/2 IMC-F106C-101 trial continues in PROC, PSOC, and NSCLC combination cohorts with chemotherapy and targeted agents. 02/25/26:- IMC-F106C-101 Phase 1/2 ovarian and NSCLC cohorts ongoing; Phase 1/2 data planned for presentation in H2 2026. 05/06/26:- IMC-F106C-101 Phase 1/2 ovarian and NSCLC cohorts enrolling; Phase 1/2 data presentation still planned H2 2026. 08/06/26:- IMC-F106C-101 ovarian and NSCLC cohorts ongoing; Phase 1/2 data expected H2 2026.
Verification
Confirm timing and program details against the company announcement or filing.